Gayatri BioOrganics Ltd

Meeting Details

• Date: 04 August 2026; at the registered office of Gayatri BioOrganics Limited.

Key Agenda Items

• Un-audited financial results and Limited Review Report for quarter ended 30 June 2026.
• Any other business with the Chair's permission.

Other Notes

• Trading window closed from 01 July 2026 until 48 hours after unaudited Q2 results.

Dematerialisation/rematerialisation status

• Certificate under Regulation 74(5) issued by the RTA for the reporting period.

Financial Performance 📊

• Board approved unaudited standalone financial results for quarter ended December 31, 2025.
• Net loss after tax for the quarter was ₹21.71 lakhs; year-to-date loss was ₹69.13 lakhs.
• Total expenses for the quarter were ₹217.1 lakhs; finance cost was ₹94.4 lakhs.
• Earnings per share (basic and diluted) for the quarter was a loss of ₹0.03 per share.
• Paid-up equity share capital remained ₹7,878.81 lakhs; net worth stood at negative ₹3,589.31 lakhs.
• Financial results prepared on a going concern basis with promoter comfort letter.

Audit and Compliance

• Independent auditor reviewed the unaudited results and issued a clean review report with no material misstatements.

Financial Performance 📊

• Revenue from operations was nil in Q3 FY2026, Q2 FY2026, and Q3 FY2025.
• Total expenses in Q3 FY2026 were ₹21.71 lakhs, up 7.9% QoQ from ₹20.13 lakhs in Q2 FY2026.
• Employee benefits expenses rose to ₹2.55 lakhs in Q3 FY2026 from ₹1.50 lakhs in Q2 FY2026.
• Finance costs increased to ₹9.44 lakhs in Q3 FY2026 from ₹8.55 lakhs in Q2 FY2026.
• Net loss after tax for Q3 FY2026 was ₹21.71 lakhs, slightly higher than ₹21.13 lakhs in Q2 FY2026.
• Year-to-date net loss after tax for nine months ended Dec 31, 2025 was ₹69.13 lakhs versus ₹55.19 lakhs prior year.

Balance Sheet & Capital

• Paid-up equity share capital remained ₹7,878.81 lakhs; net worth was negative ₹3,589.31 lakhs.

Audit & Compliance

• Independent auditor’s review found no material misstatements in unaudited Q3 FY2026 results per Ind AS 34.
• Financials prepared on a going concern basis supported by promoter comfort letter.

Business Model & Segments

• Company operates in a single segment; segment disclosures are not applicable.

Other

• No exceptional or extraordinary items reported in Q3 FY2026.

🗓️ Meeting Details

• Board meeting scheduled for 10 February 2026 at the company's registered office.

📊 Financial Results

• Approval of unaudited financial results for the quarter and nine months ended 31 December 2025.